Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ortin GlobalBOM:539287 -2.68%43 PS Ratio is 127.33 as of Aug. 15, 2026, which is 25886% above its 10-year median of 0.49. GuruFocus rates BOM:539287 with a GF Score™ of 43/100 and a GF Value™ of ₹2.48 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 951 Drug Manufacturers companies, Ortin Global ranks worse than 98.32% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ortin Global's share price is ₹15.28.
Ortin Global's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.12. Hence, Ortin Global's PS Ratio for today is 127.33.
The historical rank and industry rank for Ortin Global's PS Ratio or its related term are showing as below:
BOM:539287'
s PS Ratio Range Over the Past 10 Years
Min: 0.03 Med: 0.49 Max: 145.75
Current: 127.34
During the past 13 years, Ortin Global's highest PS Ratio was 145.75. The lowest was 0.03. And the median was 0.49.
BOM:539287's PS Ratio is ranked worse than 98.32% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs BOM:539287: 127.34
Ortin Global Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Ortin Global was -70.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -74.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -60.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -47.70% per year.
During the past 13 years, Ortin Global's highest 3-Year average Revenue per Share Growth Rate was 60.40% per year. The lowest was -74.80% per year. And the median was -21.05% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Ortin Global PS Ratio Related Terms
Ortin Global PS Ratio Historical Data
* Premium members only.
The historical data trend for Ortin Global's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Global's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ortin Global PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ortin Global's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ortin Global's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Ortin Global's PS Ratio for today is calculated as
Ortin Global's Share Price of today is ₹15.28. Ortin Global's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Ortin Global (BOM:539287) has a PS Ratio of 127.33 as of Aug. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ortin Global and its competitors. This is 25886% above median its historical median of 0.49. Over the past decade, Ortin Global's PS Ratio has ranged from 0.03 to 145.75. According to the industry distribution chart, Ortin Global ranks #935 out of 951 companies in the Drug Manufacturers industry, placing it in the top 98.3%.
Is Ortin Global's PS Ratio too high?
Ortin Global's current PS Ratio of 127.33 is 25886% above median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 145.75. The Drug Manufacturers industry median PS Ratio is 2.33. Ortin Global's value of 127.33 is 5364.8% above this industry median. Based on the distribution chart, Ortin Global ranks #935 out of 951 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ortin Global has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ortin Global's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ortin Global ranks #935 out of 951 companies for PS Ratio. This places Ortin Global in the lower half of its industry. The industry median PS Ratio is 2.33. Ortin Global's value of 127.33 is 5364.8% above this benchmark. Historically, Ortin Global's own PS Ratio has ranged from 0.03 to 145.75 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 2.33, Ortin Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ortin Global's current PS Ratio of 127.33 is 5364.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ortin Global and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ortin Global's current PS Ratio is 127.33, which is 25886% above median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortin Global stock overvalued right now?
Based on GuruFocus' analysis, Ortin Global (BOM:539287) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.48, compared to a current price of ₹15.28 — trading 516.1% above its estimated fair value. The current PS Ratio is 127.33, which is 25886% above median its 10-year median of 0.49 and 5364.8% above the Drug Manufacturers industry median of 2.33. Ortin Global's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Ortin Global (BOM:539287), the current PS Ratio is 127.33 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ortin Global (BOM:539287) Overvalued in 2026?
Based on GuruFocus' analysis, Ortin Global stock appears to be overvalued.
The current stock price of ₹15.28 is trading 516.1% above its estimated GF Value™ of ₹2.48.
GuruFocus considers Ortin Global to be Significantly Overvalued.
Key valuation signals for BOM:539287:
PS Ratio: 127.33 (25886% above median its 10-year median of 0.49)
GF Value™: ₹2.48 vs. price of ₹15.28 (516.1% above fair value)
Industry Position: 5364.8% above the Drug Manufacturers median (#935 of 951)
No single metric tells the full story. See the BOM:539287 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ortin Global Ltd is an Indian company engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helminthics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its API intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zidovudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others. Additionally, the company is also involved in the real estate business.
43GF Score
Get the complete analysis for BOM:539287
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539287 has been successfully added to your 
